Online inquiry

IVTScrip™ mRNA-Anti-HSP90, HSP90mab(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8412MR)

This product GTTS-WQ8412MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets HSP90 gene. The antibody can be applied in Candidiasis research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq XP_721353.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3636951
UniProt ID P46598
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-HSP90, HSP90mab(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ8412MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ1357MR IVTScrip™ mRNA-Anti-IL12B, ABT-874(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ABT-874
GTTS-WQ14492MR IVTScrip™ mRNA-Anti-CNR1, RYI-018(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA RYI-018
GTTS-WQ13654MR IVTScrip™ mRNA-Anti-CD19, RB4v1.2(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA RB4v1.2
GTTS-WQ2815MR IVTScrip™ mRNA-Anti-ADCYAP1R1, AMG-301(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG-301
GTTS-WQ1673MR IVTScrip™ mRNA-Anti-IL1B, ACZ885(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ACZ885
GTTS-WQ9465MR IVTScrip™ mRNA-Anti-KIR3DL2, IPH4102(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IPH4102
GTTS-WQ7311MR IVTScrip™ mRNA-Anti-FGFR2, FPA-144(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA FPA-144
GTTS-WQ7828MR IVTScrip™ mRNA-Anti-GLP1R, GSK 716155(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GSK 716155
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW